ASAP Act
- Bill Number
- S. 3267
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-11-20: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S8278-8279)
- Last Updated
- 2026-06-24T11:03:29Z
AI-Generated Summary
Purpose
The Alzheimer's Screening and Prevention Act (ASAP Act) aims to expand Medicare coverage to include early detection screening tests for Alzheimer's disease and related dementias, focusing on blood-based and equivalent tests to identify the condition in its pre-symptomatic or early stages. This legislation seeks to promote earlier diagnosis and intervention for these progressive brain disorders, which affect memory, thinking, and behavior.
Key Provisions
- Coverage Addition: Medicare Part B (which covers outpatient services) will cover "Alzheimer's disease and related dementias early detection screening tests" starting January 1, 2028.
- Definition of Covered Tests:
- Tests must be approved, cleared, or classified by the Food and Drug Administration (FDA) under specific regulatory pathways (e.g., 510(k) clearance for devices similar to existing ones, de novo classification for novel low-risk devices, or full premarket approval).
- Primarily includes genomic sequencing tests using blood or blood products.
- Also covers equivalent tests, such as those analyzing cell-free nucleic acids (genetic material in blood), multiplex panels (tests checking multiple markers), whole genome/exome/transcriptome sequencing, protein expression tests, or medical imaging based on blood, tissue, urine, or other biospecimens—as determined appropriate by the Secretary of Health and Human Services (HHS) for comparable accuracy.
- Payment Mechanism: These tests will be paid under Medicare's existing clinical diagnostic laboratory fee schedule, similar to other lab services.
Significant Changes to Existing Law
- Amends Section 1861(s)(2) of the Social Security Act by adding a new subparagraph (KK) to explicitly include these screening tests as a covered benefit under Medicare Part B.
- Adds a new subsection (nnn) defining the tests in detail, which did not previously exist.
- Modifies Section 1833(h)(1)(A) to incorporate payment for these tests into the fee schedule for diagnostic lab services, integrating them seamlessly without creating a separate payment system.
These changes build on current Medicare coverage for dementia-related services (like cognitive assessments) but introduce specific coverage for advanced, non-invasive screening tools not previously reimbursed.
Potential Impacts
- On Citizens: Medicare beneficiaries, particularly older adults (over 65) at risk for dementia, could access earlier screenings without out-of-pocket costs (subject to deductibles/coinsurance), potentially leading to timely treatments that slow disease progression and improve quality of life. This may reduce family caregiving burdens but could increase overall healthcare utilization.
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS), part of HHS, will need to implement coverage rules, update payment systems, and coordinate with the FDA on test approvals, possibly increasing administrative workload and program costs (estimated in billions over time due to the aging population).
- On International Relations: Minimal direct impact, though it could influence global standards for dementia screening by promoting U.S.-developed tests, potentially benefiting international biotech collaborations or exports of approved diagnostics.
Main Stakeholders Affected
- Medicare Enrollees: Primary beneficiaries, especially the estimated 6 million+ Americans with Alzheimer's, gaining access to preventive screenings.
- Healthcare Providers: Doctors and clinics offering these tests, who may see increased demand for dementia care services.
- Diagnostic Companies: Biotech and pharmaceutical firms developing blood-based tests (e.g., those using genomic or proteomic analysis), incentivized by guaranteed Medicare reimbursement to innovate.
- Government Entities: HHS, CMS, and FDA, responsible for oversight, approvals, and funding allocation from the Medicare Trust Fund.
- Advocacy Groups: Organizations like the Alzheimer's Association, which may support broader access to care.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens preventive care under Medicare by clarifying coverage for emerging technologies, reducing ambiguity in reimbursing FDA-approved tests. It delegates authority to the HHS Secretary for defining "equivalent" tests, allowing flexibility without needing new legislation for future innovations.
- Constitutional: No apparent challenges; aligns with Congress's power to regulate interstate commerce and provide for public welfare through social insurance programs like Medicare.
- Political: Bipartisan introduction (by Sens. Collins, Cortez Masto, Capito, and Warner) signals broad support for addressing the growing dementia crisis amid an aging population. Could spark debates on federal spending (adding to Medicare's $800+ billion annual budget) versus long-term savings from early intervention, potentially influencing future healthcare reform discussions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (40)
Sen. Cortez Masto, Catherine [D-NV], Sen. Capito, Shelley Moore [R-WV], Sen. Warner, Mark R. [D-VA], Sen. Banks, Jim [R-IN], Sen. Lankford, James [R-OK], Sen. Kennedy, John [R-LA], Sen. Duckworth, Tammy [D-IL], Sen. Booker, Cory A. [D-NJ], Sen. Moran, Jerry [R-KS], Sen. Tillis, Thomas [R-NC], Sen. Daines, Steve [R-MT], Sen. Fischer, Deb [R-NE], Sen. Murkowski, Lisa [R-AK], Sen. Scott, Rick [R-FL], Sen. Cramer, Kevin [R-ND], Sen. Hyde-Smith, Cindy [R-MS], Sen. Rounds, Mike [R-SD], Sen. Britt, Katie Boyd [R-AL], Sen. Klobuchar, Amy [D-MN], Sen. Coons, Christopher A. [D-DE], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Armstrong, Alan [R-OK], Sen. Wicker, Roger F. [R-MS], Sen. Kelly, Mark [D-AZ], Sen. Hoeven, John [R-ND], Sen. Hirono, Mazie K. [D-HI], Sen. Smith, Tina [D-MN], Sen. Van Hollen, Chris [D-MD], Sen. Cantwell, Maria [D-WA], Sen. Shaheen, Jeanne [D-NH], Sen. Reed, Jack [D-RI], Sen. Kim, Andy [D-NJ], Sen. Slotkin, Elissa [D-MI], Sen. Blunt Rochester, Lisa [D-DE], Sen. Gallego, Ruben [D-AZ], Sen. Risch, James E. [R-ID], Sen. Welch, Peter [D-VT], Sen. Padilla, Alex [D-CA], Sen. Heinrich, Martin [D-NM], Sen. McCormick, David [R-PA]
Recent Actions
- 2025-11-20: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S8278-8279)
- 2025-11-20: Introduced in Senate
Bill Versions
- Alzheimer's Screening and Prevention Act — issued 2025-11-20 — PDF (3 pages)